Navidea brings Lymphoseek to U.S. market

05/1/2013 | Wall Street Journal, The

Navidea Biopharmaceuticals is launching its lymphatic mapping radiopharmaceutical Lymphoseek in the U.S., the company announced today. Navidea has partnered with Cardinal Health to distribute the product to U.S. health care providers. "Commercialization of Lymphoseek in the U.S. marks a pivotal milestone for Navidea, and we are pleased to deliver this innovative diagnostic imaging agent to patients with breast cancer and melanoma," said Navidea President and CEO Dr. Mark Pykett. Lymphatic mapping helps trace the spread of cancer.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President for Product Delivery
National Committee for Quality Assurance
Washington, DC
SENIOR REGULATORY AFFAIRS SPECIALIST - 13000006XJ
Abbott
Oakland, CA
FDA/Post Drug Approval Attorney
Quarles & Brady
Washington, DC
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
FDA/Device Technology Attorney
Quarles & Brady
Washington, DC